Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Jun;38(3):581-599.
doi: 10.1007/s10557-022-07409-w. Epub 2022 Dec 17.

PrevAleNce and Associated factors of inappropriaTe dosing of direct Oral anticoaguLants In pAtients with Atrial Fibrillation: the ANATOLIA-AF Study

Umut Kocabaş  1 , Isil Ergin  2 , Veysel Yavuz  3 , Selda Murat  4 , Ibrahim Özdemir  5 , Ömer Genç  6 , Cihan Altın  7 , Haşim Tüner  8 , Bengisu Keskin Meriç  9 , Ali Çoner  10 , Elif İlkay Yüce  11 , Bedrettin Boyraz  12 , Onur Aslan  13 , Ahmet Dal  7 , Taner Şen  14 , Ersin İbişoğlu  15 , Aslan Erdoğan  15 , Mehmet Özgeyik  16 , Mevlüt Demir  14 , Ziya Gökalp Bilgel  17 , Büşra Güvendi Şengör  18 , Örsan Deniz Urgun  19 , Mustafa Doğduş  20 , Deniz Dilan Naki Tekin  15 , Sinem Çakal  21 , Sercan Çayırlı  22 , Arda Güler  23 , Dilay Karabulut  24 , Onur Dalgıç  25 , Osman Uzman  26 , Bektaş Murat  16 , Şeyda Şahin  27 , Umut Karabulut  28 , Tarık Kıvrak  29 , Muharrem Said Coşgun  30 , Ferhat Özyurtlu  31 , Mehmet Kaplan  32 , Emre Özçalık  33 ; ANATOLIA-AF . study investigators
Collaborators, Affiliations
Observational Study

PrevAleNce and Associated factors of inappropriaTe dosing of direct Oral anticoaguLants In pAtients with Atrial Fibrillation: the ANATOLIA-AF Study

Umut Kocabaş et al. Cardiovasc Drugs Ther. 2024 Jun.

Erratum in

Abstract

Purpose: Inappropriate dosing of direct oral anticoagulants is associated with an increased risk of stroke, systemic embolism, major bleeding, cardiovascular hospitalization, and death in patients with atrial fibrillation. The main goal of the study was to determine the prevalence and associated factors of inappropriate dosing of direct oral anticoagulants in real-life settings.

Methods: This study was a multicenter, cross-sectional, observational study that included 2004 patients with atrial fibrillation. The study population was recruited from 41 cardiology outpatient clinics between January and May 2021. The main criteria for inappropriate direct oral anticoagulant dosing were defined according to the recommendations of the European Heart Rhythm Association.

Results: The median age of the study population was 72 years and 58% were women. Nine-hundred and eighty-seven patients were prescribed rivaroxaban, 658 apixaban, 239 edoxaban, and 120 dabigatran. A total of 498 patients (24.9%) did not receive the appropriate dose of direct oral anticoagulants. In a logistic regression model, advanced age, presence of chronic kidney disease and permanent atrial fibrillation, prescription of reduced doses of direct oral anticoagulants or edoxaban treatment, concomitant use of amiodarone treatment, and non-use of statin treatment were significantly associated with potentially inappropriate dosing of direct oral anticoagulants.

Conclusion: The study demonstrated that the prevalence of inappropriate direct oral anticoagulant dosing according to the European Heart Rhythm Association recommendations was 24.9% in patients with atrial fibrillation. Several demographic and clinical factors were associated with the inappropriate prescription of direct oral anticoagulants.

Keywords: Atrial fibrillation; Direct oral anticoagulants; Inappropriate dosing; Stroke; Systemic embolism.

PubMed Disclaimer

References

    1. Hindricks G, Potpara T, Dagres N, ESC Scientific Document Group, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373–498. - DOI - PubMed
    1. Kocabas U, Kaya E, Avcı G. Novel oral anticoagulants in non-valvular atrial fibrillation: pharmacological properties, clinical trials, guideline recommendations, new antidote drugs and real-world data. Int J Cardiovasc Acad. 2016;2:167–73. - DOI
    1. Connolly SJ, Ezekowitz MD, Yusuf S, RE-LY Steering Committee Investigators, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:11391151. - DOI
    1. Patel MR, Mahaffey KW, Garg J, ROCKET AF Investigators, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883891. - DOI
    1. Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981992. - DOI

Publication types

MeSH terms

LinkOut - more resources